Pharma
Group B Streptococcus vaccines - not just for the baby
This month VacZine Analytics, a specialist in infectious diseases and vaccines commercial analysis publishes a brand-new global demand assessment for Group B Streptococcus (GBS) vaccines. ...
Guardtech Group: the growing family business with global aspirations
Cleanroom construction specialists determined to retain their family values as individual brands continue to thrive in UK and beyond ...
Cresset shares September 2023 news
Welcome to the September Cresset Newsletter Optimize your decision-making across the entire design-make-test-analyze (DMTA) cycle with this month's collection of CADD software features, expert scientific opinion, and first-class drug discovery research resources. You can subscrib...
Roundtable: Transitioning Medical Affairs to strategically co-lead clinical development and commercialization efforts
This article was published by Medical Affairs Professional Society (MAPS).
Streamline sharing of CADD data seamlessly to accelerate your drug design process
Introduction The globalized outsourcing model of modern drug discovery is driving efficiencies across the Design-Make-Test-Analyze (DMTA) cycle. With projects typically involving multiple specialist CROs, effective communication is key to ensuring the success of these collaborations. ...
Webinar: Metabolism prediction, 3D virtual screening and more – meet StarDrop 7.5
Want to discover next generation drug discovery software? Join Optibrium’s Chief Scientific Officer Ed Champness to explore the exciting new features in the latest release of StarDrop, built to elevate your drug discovery projects. These include: ...
Optibrium releases powerful metabolism prediction capability in next generation StarDrop software
Cambridge, UK – Optibrium, a leading developer of software and AI solutions for drug discovery, launches the latest version of its drug discovery platform, StarDrop 7.5, introducing a powerful module for drug metabolism prediction. ...
Ion channel drug developer Maxion Therapeutics appoints Eva-Lotta Allan as Chair of its Board of Directors
Maxion Therapeutics (“Maxion”), the biotechnology company developing antibody-based drugs for previously untreatable ion channel- and GPCR-driven diseases, announced the appointment of senior industry leader Eva-Lotta Allan as the Chair of its Board of Directors. The announcement comes ...
Lunch & Learn: Early Phase Clinical Trials in Australia - Fast-Tracking Your Development Program
Join us for a Lunch and Learn session to discuss the early phase clinical trial landscape and capabilities in Australia, how this could help accelerate your clinical development program, and benefits of including this region in your trial design. ***This is a free event and open to a...